{"gene":"RIPK2","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1998,"finding":"RICK (RIPK2) was identified as a novel serine-threonine kinase containing an N-terminal kinase domain and C-terminal CARD. It physically interacts with CLARP (a caspase-like molecule binding FADD and caspase-8), and its expression promoted caspase-8 activation and apoptosis induced by Fas ligand, FADD, and caspase-8. A kinase-dead mutant (K38M) functioned as a dominant-negative inhibitor of CD95-mediated apoptosis, demonstrating both kinase domain and CARD are required for pro-apoptotic function.","method":"Co-immunoprecipitation, overexpression, dominant-negative mutagenesis, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding demonstrated, mutagenesis of ATP-binding site, multiple functional readouts in a single study","pmids":["9575181"],"is_preprint":false},{"year":1998,"finding":"CARDIAK (RIPK2) was identified as a RIP-like kinase containing a CARD that specifically interacts with caspase-1 via CARD-CARD interaction. This interaction correlated with processing of pro-caspase-1 to the active p20 subunit. Overexpression activated both NF-κB and JNK, and CARDIAK interacted with TRAF-1 and TRAF-2; dominant-negative TRAF-2 inhibited CARDIAK-induced NF-κB activation.","method":"Co-immunoprecipitation, overexpression, NF-κB/JNK reporter assays, dominant-negative TRAF-2","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple binding partners identified by Co-IP, functional NF-κB and JNK activation assays, caspase-1 processing demonstrated","pmids":["9705938"],"is_preprint":false},{"year":2000,"finding":"RICK (RIPK2) was shown to interact with IKKγ (NEMO) via its intermediate region (not its kinase domain), linking NOD1/Nod1-mediated proximity signaling to IKK activation. Enforced oligomerization of RICK was sufficient to activate NF-κB, and a mutant IKKγ deficient in IKKα/β binding blocked RICK-induced NF-κB activation. This defined an induced-proximity model for NF-κB activation downstream of Nod1.","method":"Co-immunoprecipitation, enforced oligomerization, dominant-negative IKKγ, NF-κB reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, forced oligomerization, dominant-negative), mechanistic pathway placement established","pmids":["10880512"],"is_preprint":false},{"year":2002,"finding":"Rip2 (RIPK2) was recruited to TLR2 signaling complexes after ligand stimulation. Rip2-deficient cells showed reduced cytokine production upon TLR2/3/4 stimulation but not TLR9, indicating Rip2 acts downstream of TLR2/3/4 but not TLR9. Rip2-deficient cells were also hyporesponsive to IL-1 and IL-18 receptor signaling and to Nod proteins. Rip2-deficient T cells showed severely reduced NF-κB activation, IL-2 production, proliferation on TCR engagement, and impaired TH1 differentiation.","method":"Rip2-deficient mouse cells, co-immunoprecipitation (recruitment to TLR2 complex), cytokine assays, NF-κB activation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout combined with Co-IP recruitment assay and multiple functional readouts across innate and adaptive immunity","pmids":["11894098"],"is_preprint":false},{"year":2006,"finding":"NMR solution structure of the NOD1 CARD was determined. Mutagenesis revealed that CARD-CARD interaction between NOD1 and RICK is critically dependent on three acidic residues on NOD1 CARD and three basic residues on RICK CARD, indicating a strong electrostatic component to the NOD1-RICK interaction essential for downstream NF-κB signaling.","method":"NMR structure determination, site-directed mutagenesis, co-immunoprecipitation from cell lysates, NF-κB reporter assay","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure combined with mutagenesis and functional NF-κB validation; mechanistic interface defined","pmids":["17054981"],"is_preprint":false},{"year":2007,"finding":"RICK (RIPK2) is required for innate immune responses to Nod1 and Nod2 agonists but not for responses to highly purified TLR agonists (LPS, etc.) in macrophages and mice. RICK-null macrophages were defective in Nod1/Nod2-mediated NF-κB activation and cytokine production, while TLR-mediated responses were intact. This definitively placed RICK downstream of Nod1/Nod2 but not TLRs.","method":"RICK-deficient mouse macrophages, cytokine ELISA, NF-κB activation assays, in vivo infection models","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with clean pathway placement, multiple agonists tested, both in vitro and in vivo, independently confirmed by multiple labs","pmids":["17277144"],"is_preprint":false},{"year":2007,"finding":"RICK undergoes K63-linked polyubiquitination at lysine 209 (K209) in its kinase domain upon Nod1 or Nod2 stimulation or RICK oligomerization. This ubiquitination is essential for IKK activation and cytokine/chemokine secretion but does not require RICK kinase activity or alter RICK-NEMO interaction. K63-polyubiquitinated RICK recruits TAK1, linking TAK1 to IKK complexes as a critical step in Nod-mediated NF-κB activation.","method":"Ubiquitination assays, K209 mutagenesis, co-immunoprecipitation, cytokine secretion assays, TAK1-deficient cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-specific mutagenesis (K209), in-cell ubiquitination assays, genetic (TAK1-deficient cells) and biochemical validation of TAK1 recruitment","pmids":["18079694"],"is_preprint":false},{"year":2007,"finding":"NOD2 promotes the membrane recruitment of RICK; membrane-anchored NOD2 recruits RICK to the plasma membrane where RICK signaling is optimal. Artificial attachment of RICK at the plasma membrane caused constitutive strong NF-κB activation and IL-8 secretion. The NOD2 1007FS Crohn's disease mutant was unable to signal from the plasma membrane, correlating with impaired RICK recruitment.","method":"Subcellular fractionation, membrane targeting constructs, immunofluorescence, NF-κB reporter assays, IL-8 secretion measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiments with functional consequence, artificial membrane targeting with constitutive activation, disease-relevant mutant analysis","pmids":["17355968"],"is_preprint":false},{"year":2012,"finding":"The Yersinia pseudotuberculosis effector YopJ acetylates critical sites in the activation loops of RICK and TAK1 kinases, blocking their activity. The catalytically inactive YopJ(C172A) mutant failed to acetylate RICK or TAK1 and could not subvert Nod2 signaling. YopJ acetylation of RICK also decreased the affinity of Nod2 for RICK and concurrently redirected Nod2 to interact with and activate caspase-1.","method":"In-cell acetylation assay, catalytically inactive mutant YopJ, co-immunoprecipitation, caspase-1 activation assay, IL-1β measurement","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic modification (acetylation) demonstrated with catalytically inactive control, multiple orthogonal readouts","pmids":["22520462"],"is_preprint":false},{"year":2012,"finding":"P. gingivalis infection of human aortic endothelial cells caused rapid cleavage of RIPK2. Cleavage was not observed with apoptotic stimuli or TLR/NOD agonists, was inhibited by a lysine-specific gingipain (Kgp) inhibitor, and was absent with an isogenic Kgp-deficient P. gingivalis mutant. Direct proteolysis of RIPK2 by P. gingivalis was confirmed in a cell-free system, defining Kgp as the protease responsible.","method":"Cell-free proteolysis assay, Kgp-specific inhibitor, isogenic Kgp-deficient mutant, immunoblotting","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-free reconstitution of proteolysis, isogenic mutant control, specific inhibitor, multiple orthogonal validations","pmids":["22685397"],"is_preprint":false},{"year":2015,"finding":"RIPK2 kinase activity is dispensable for NF-κB activation per se, but type II kinase inhibitors (ponatinib, regorafenib) that displace the activation segment block RIPK2 autophosphorylation, RIPK2 ubiquitination, and inflammatory NF-κB signaling. Type I (ATP-competitive) inhibition was only poorly effective. A crystal structure of RIPK2 bound to ponatinib was determined, revealing the activation segment conformation and an allosteric site.","method":"Crystal structure (first RIPK2 crystal structure), kinase inhibitor profiling, autophosphorylation assay, ubiquitination assay, NF-κB reporter, monocyte cytokine production","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — first crystal structure of RIPK2, type I vs type II inhibitor comparison, ubiquitination and NF-κB mechanistic assays","pmids":["26320862"],"is_preprint":false},{"year":2015,"finding":"HIV-1 protease cleaves RIPK2 during infection of T cells. Cleavage was prevented by HIV-1 protease inhibitor but not by inhibitors of RT or integrase. Cleavage of RIPK1 (which was identified at a defined PR cleavage site) disrupted RIPK1/RIPK3 complex formation and NF-κB induction; analogous cleavage of RIPK2 is proposed as a viral immune evasion strategy.","method":"HIV-1 infection of T cells, stage-specific inhibitors, co-immunoprecipitation (RIPK1/RIPK3 complex), NF-κB assay, site mutagenesis (RIPK1 cleavage site)","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — RIPK2 cleavage during HIV infection shown with inhibitor controls, but direct mapping of RIPK2 cleavage site and functional consequence for RIPK2 not fully established in the abstract","pmids":["26297639"],"is_preprint":false},{"year":2015,"finding":"WEHI-345, a selective RIPK2 kinase inhibitor, delays but does not abolish RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation, WEHI-345 prevents cytokine production in vitro and in vivo, demonstrating that kinase activity timing is critical for productive immune responses and that RIPK2 kinase activity is required for proper NOD signaling.","method":"Selective kinase inhibitor, ubiquitylation kinetics assay, NF-κB activation kinetics, cytokine production assay in vitro/in vivo, EAE model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — selective inhibitor with biochemical mechanistic dissection, in vitro and in vivo validation, independently replicated concept","pmids":["25778803"],"is_preprint":false},{"year":2018,"finding":"RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling. Instead, kinase inhibitors function by antagonizing the XIAP-binding interaction. The XIAP binding site on RIPK2 was mapped to the loop between β2 and β3 of the N-lobe of the kinase domain, in close proximity to the ATP-binding pocket. Inhibitor binding to the ATP pocket sterically blocks the RIPK2-XIAP interaction, preventing XIAP-mediated ubiquitination of RIPK2 and downstream NOD2 signaling.","method":"XIAP binding mapping, site-directed mutagenesis, kinase activity assays, co-immunoprecipitation, in vivo NOD2 signaling assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural mapping of XIAP binding site, mutagenesis, multiple inhibitors with orthogonal mechanistic validation","pmids":["30026309"],"is_preprint":false},{"year":2019,"finding":"RIPK2 forms detergent-insoluble, higher-order molecular complexes (speck-like structures) in the cytosol upon infection with invasive enteropathogenic bacteria. Complex formation required RIPK2 autophosphorylation at Y474, was influenced by S176 phosphorylation, and depended on the CARD of NOD1 or NOD2. XIAP counteracts RIPK2 complex formation; mutation of XIAP ubiquitylation sites on RIPK2 enhanced complex formation, identifying XIAP-mediated ubiquitination as a brake on RIPK2 aggregation.","method":"Detergent fractionation, autophosphorylation site mutagenesis (Y474, S176), XIAP ubiquitylation site mutagenesis, bacterial infection model","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple phosphorylation site mutants, XIAP ubiquitylation site mutants, detergent fractionation, bacterial infection model — all orthogonal","pmids":["31350258"],"is_preprint":false},{"year":2020,"finding":"A regulatory region on RIPK2 (distinct from K209) is required for XIAP binding and downstream NOD signaling. Using endogenous FLAG-RIPK2 knock-in mice and site-directed mutagenesis, K48-linked ubiquitination at specific residues was found to control RIPK2 stability, while distinct sites govern XIAP binding and signaling. K209 ubiquitination was not detected during NOD2 signaling at endogenous levels, contrasting with earlier overexpression data.","method":"CRISPR/Cas9 FLAG-RIPK2 knock-in mice, site-directed mutagenesis, mass spectrometry-based post-translational modification mapping, NOD2 signaling assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — endogenous-level analysis via CRISPR knock-in, MS-based PTM mapping, mutagenesis; contradicts prior K209 ubiquitination claim under endogenous conditions","pmids":["32954645"],"is_preprint":false},{"year":2021,"finding":"ATG16L1 physically binds the RICK/RIPK2 kinase domain and negatively regulates TLR2-mediated NF-κB activation and pro-inflammatory cytokine responses by inhibiting the interaction between TLR2 and RICK/RIPK2. ATG16L1 binding suppresses NF-κB activation by down-regulating RICK polyubiquitination.","method":"Co-immunoprecipitation in HEK293 cells and primary human dendritic cells, NF-κB activation assays, cytokine measurement","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP in two cell systems, functional NF-κB assay, single lab","pmids":["32909611"],"is_preprint":false},{"year":2022,"finding":"RIPK2 stabilizes c-Myc and promotes prostate cancer metastasis by binding to and activating MKK7, which was identified as a direct c-Myc-S62 kinase. This defines a noncanonical RIPK2/MKK7/c-Myc pathway distinct from the canonical NOD/NF-κB pathway. RIPK2 inhibition inactivated MKK7 and c-Myc-S62 phosphorylation.","method":"Co-immunoprecipitation, multi-level proteomics, RIPK2 knockout, phosphorylation assays (c-Myc S62), kinase inhibitors, in vivo metastasis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifying RIPK2-MKK7 binding, genetic KO, multi-level proteomics, pharmacological inhibition, in vivo validation","pmids":["35115556"],"is_preprint":false},{"year":2014,"finding":"NOD2 activation results in increased IRF4 expression, which then binds TRAF6 and RICK. IRF4 binding leads to inhibition of K63-linked polyubiquitination of both TRAF6 and RICK, thereby downregulating NF-κB activation. This defines a negative feedback mechanism where NOD2 activation ultimately suppresses TLR-mediated inflammatory responses.","method":"Co-immunoprecipitation (IRF4 binding to TRAF6 and RICK), ubiquitination assays (K63-linkage), in vivo colitis model with MDP/IRF4 treatment","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of IRF4-RICK complex, K63-ubiquitination assays, in vivo validation, single lab","pmids":["24670424"],"is_preprint":false},{"year":2005,"finding":"RIP2/RICK/CARDIAK is a direct substrate for pyridinyl imidazole p38 MAPK inhibitors (SB220025, SB203580, PD169316) in vitro, with inhibition at concentrations comparable to p38 inhibition. RIP2 autophosphorylation and its ability to phosphorylate myelin basic protein (Km=2.1 μM) and histone H3 (Km=0.65 μM) were identified as new substrates. A conserved threonine in the RIP2 kinase domain (equivalent to p38) was required for inhibitor sensitivity.","method":"In vitro kinase autophosphorylation assay, substrate phosphorylation assay (MBP, histone H3), Km determination, threonine mutant analysis","journal":"Molecular and cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted kinase assay with mutagenesis confirming mechanism of inhibitor sensitivity; identified new substrates","pmids":["15724446"],"is_preprint":false},{"year":2003,"finding":"CARD6 specifically binds Nod1 (CARD4) and Cardiak (RIPK2) by immunoprecipitation but not other CARD family proteins, and acts as a selective modulator suppressing NF-κB induction by Nod1 or Cardiak. Cardiak and Nod1 had opposing effects on CARD6 phosphorylation and expression. CARD6 did not interfere with CARD-containing adaptor Bcl10 or TNF-α-induced NF-κB nor with caspase-1-dependent IL-1β secretion.","method":"Co-immunoprecipitation, NF-κB reporter transfection assay, phosphorylation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and functional reporter assay, specificity confirmed by testing multiple CARD proteins, but single lab, no structural validation","pmids":["12775719"],"is_preprint":false},{"year":2003,"finding":"RICK activates NF-κB through its intermediate domain (not kinase activity, as both kinase-active and kinase-inactive forms activated NF-κB) and this NF-κB activation potently blocks HCMV replication in human fibroblasts. A stable IκB inhibitor reversed RICK's anti-HCMV effect. RICK expression synergized with HCMV infection in inducing IFN-β, which was identified as a downstream component of the RICK inhibitory pathway.","method":"Kinase-active and kinase-dead RICK overexpression, stable IκB inhibitor, supernatant IFN-β transfer experiments, viral replication assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead vs active domain dissection, stable IκB reversal, IFN-β identification by supernatant transfer; single lab","pmids":["14670961"],"is_preprint":false},{"year":2003,"finding":"The CARD of RICK folds as an α-helical Greek key structure with marginal stability (ΔG = 3.0 kcal/mol). Equilibrium folding follows a two-state mechanism, but unfolding and refolding kinetics are complex with at least three non-native conformations and kinetically trapped species, likely involving parallel folding pathways rather than prolyl isomerism.","method":"Equilibrium and stopped-flow kinetic folding spectroscopy, chemical denaturation, guanidinium/salt titrations","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — rigorous biophysical characterization of CARD folding, but single lab and focuses on folding mechanism rather than signaling function","pmids":["12755636"],"is_preprint":false},{"year":2013,"finding":"NOD2 activation by PGN in oligodendrocyte precursor cells (OPCs) leads to RIPK2 recruitment and phosphorylation of RIPK2, followed by phosphorylation of neuronal nitric oxide synthase (nNOS). This increases NOS activity and NO accumulation leading to mitochondrial respiratory enzyme inhibition (complex I and IV), reduced mitochondrial membrane potential, and cytochrome-C release. Intracerebral PGN injection in rats caused CNS demyelination.","method":"OPC cultures, NOD2 ligand stimulation, RIPK2 phosphorylation assay, nNOS phosphorylation, NOS activity assay, specific inhibitors (7-NI vs L-canavanine), mitochondrial function assays, in vivo rat injection","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation cascade demonstrated with selective inhibitors, in vitro and in vivo, but single lab","pmids":["24169446"],"is_preprint":false},{"year":2020,"finding":"MYSM1 deubiquitinates RIPK2 and dephosphorylates RIPK2 at S176 by recruiting protein phosphatase 2A (PP2A) to RIPK2. This attenuates NF-κB and MAPK signaling. The Ripk2S176D (phosphomimetic) mutation accelerated OA pathogenesis, while Ripk2 silencing or Ripk2S176A mutation deactivated NF-κB and MAPK pathways and counteracted the role of MYSM1.","method":"Co-immunoprecipitation (MYSM1-PP2A-RIPK2 complex), S176 phosphomimetic and phospho-dead mutagenesis in mice, deubiquitination assays, NF-κB/MAPK signaling assays, in vivo OA mouse model","journal":"Bone research","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical deubiquitination and dephosphorylation assays, phospho-site mutagenesis in vivo, multiple orthogonal methods identifying MYSM1-PP2A as writer/eraser of RIPK2 PTMs","pmids":["39746943"],"is_preprint":false},{"year":2024,"finding":"YOD1, a deubiquitinating enzyme, inhibits K48-linked polyubiquitination of RIPK2, preventing its proteasomal degradation and thereby increasing RIPK2 abundance to enhance NOD2 signaling. YOD1-deficient mice show increased susceptibility to DSS-induced colitis, and the protective function of the NOD2 ligand MDP in experimental colitis was abolished in YOD1-deficient mice.","method":"YOD1-deficient mice, bone marrow transplantation, K48-ubiquitination assays, NOD2 signaling assays in macrophages, DSS colitis model","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with K48-ubiquitination linkage assay, bone marrow transplant epistasis, in vivo colitis model, multiple orthogonal validations","pmids":["39333628"],"is_preprint":false},{"year":2024,"finding":"N4BP3 interacts with RIPK2 (demonstrated by co-immunoprecipitation) and promotes K63-linked ubiquitination of RIPK2, further promoting the NOD2-MAPK/NF-κB pathway and increasing pro-inflammatory cytokine release. N4BP3 knockdown reduced MDP-induced inflammatory cytokines and NOD2-pathway phosphoproteins (ERK1/2, JNK, P38, NF-κB p65).","method":"Co-immunoprecipitation, K63-ubiquitination assay, siRNA knockdown, MDP stimulation, phosphoprotein immunoblotting, in vivo DSS colitis","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrated N4BP3-RIPK2 interaction, K63-ubiquitination assay, functional signaling readouts; single lab","pmids":["39420190"],"is_preprint":false},{"year":2025,"finding":"RIPK2 promotes colorectal cancer metastasis through a mechanism involving K63-linked ubiquitination of RIPK2 (triggered by MDP/NOD2 activation), and RIPK2 interaction with the E3 ubiquitin ligase ITCH which balances K63-ubiquitination of RIPK2 with K48-ubiquitination of YAP (leading to YAP degradation). RIPK2 knockdown increased ITCH-mediated K48-ubiquitination and degradation of YAP. GSK583 (RIPK2 inhibitor) disrupted YAP stability.","method":"Co-immunoprecipitation (RIPK2-ITCH interaction), ubiquitination linkage assays (K63/K48), RIPK2 knockdown, pharmacological inhibition, in vivo xenograft and metastasis models, proteomic analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, linkage-specific ubiquitination assays, pharmacological inhibitor, in vivo model; single lab, relatively recent study","pmids":["40185717"],"is_preprint":false},{"year":2022,"finding":"RIPK2 interacts with PRKCI (as shown by co-immunoprecipitation and immunofluorescence) to enhance phosphorylation of NF-κB, JNK, and ERK downstream. RIPK2 knockout suppressed subcutaneous tumor growth, liver metastasis, inhibited autophagosome formation, and increased ROS production and apoptosis in pancreatic cancer cells.","method":"Co-immunoprecipitation, immunofluorescence, RIPK2 knockout, phosphorylation immunoblotting, in vivo xenograft and metastasis models","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of RIPK2-PRKCI, phosphorylation assays, genetic KO with in vivo validation; single lab","pmids":["37016317"],"is_preprint":false},{"year":2022,"finding":"Card9 inhibits NLRP3 inflammasome activation in macrophages by recruiting Ripk2. Ripk2 competitively binds Caspase-1, preventing the normal ASC-Caspase-1 interaction required for NLRP3 inflammasome assembly. Overexpression of Ripk2 alleviated septic intestinal injury caused by Card9 deficiency.","method":"Co-immunoprecipitation (Card9-Ripk2; Ripk2-Caspase-1 vs ASC-Caspase-1 competition), Card9-knockout mice, NLRP3 inflammasome activation assay, Ripk2 overexpression rescue","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — competitive Co-IP dissecting caspase-1 binding partners, genetic KO and rescue with overexpression; single lab, novel mechanism","pmids":["35618701"],"is_preprint":false},{"year":2018,"finding":"A co-crystal structure of RIPK2 bound to the activation loop targeting inhibitor CSR35 revealed a resolved activation loop with an ionic interaction between the inhibitor carboxylic acid and the side-chain of Lys169 in the activation loop, providing structural basis for activation-loop-targeting type II inhibitor strategy and >10-fold selectivity over VEGFR2.","method":"Co-crystal structure of RIPK2-CSR35 complex, biochemical kinase inhibition assay","journal":"Bioorganic & medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with explicit activation loop resolution and selectivity-determining ionic contact identified; single lab","pmids":["29409752"],"is_preprint":false}],"current_model":"RIPK2 (RICK/CARDIAK/CARD3) is a dual-specificity serine/threonine/tyrosine kinase with an N-terminal kinase domain and C-terminal CARD that acts as the obligate adaptor kinase downstream of NOD1 and NOD2 pattern-recognition receptors: upon bacterial peptidoglycan sensing, RICK is recruited via homotypic CARD-CARD interactions (requiring acidic NOD1 and basic RICK CARD residues) to the plasma membrane where its activity is optimal; it undergoes autophosphorylation (including at Y474 and S176) and K63-linked polyubiquitination (facilitated by XIAP as the primary E3 ligase, and regulated by N4BP3 and other ligases, with K48-linked ubiquitination by opposing enzymes controlling its stability); the scaffolding function—specifically the RIPK2-XIAP protein-protein interaction mediated by the β2-β3 loop of the kinase N-lobe—is mechanistically more critical than catalytic activity for recruiting TAK1 and activating the IKK complex to drive NF-κB and MAPK-dependent pro-inflammatory cytokine production; XIAP-mediated ubiquitination also prevents formation of higher-order RIPK2 speck-like complexes; in addition to the canonical NOD pathway, RIPK2 signals downstream of T-cell receptors, IL-1/IL-18 receptors, and certain TLRs, mediates a noncanonical MKK7/c-Myc pathway relevant to cancer metastasis, and can be inactivated by pathogen-derived proteases (P. gingivalis Kgp gingipain, HIV-1 protease) and bacterial effectors (Yersinia YopJ acetylation) as immune evasion mechanisms."},"narrative":{"mechanistic_narrative":"RIPK2 (RICK/CARDIAK/CARD3) is a dual-domain serine/threonine kinase with an N-terminal kinase domain and a C-terminal CARD that functions as the obligate adaptor kinase coupling the cytosolic pattern-recognition receptors NOD1 and NOD2 to NF-κB and MAPK-driven pro-inflammatory cytokine production [PMID:17277144, PMID:10880512]. Recruitment occurs through homotypic CARD-CARD engagement that is critically dependent on a set of acidic residues on the NOD1 CARD pairing with basic residues on the RIPK2 CARD [PMID:17054981], and NOD2 directs RIPK2 to the plasma membrane where signaling is optimal—a step disrupted by the Crohn's disease-associated NOD2 1007FS mutant [PMID:17355968]. Once recruited, RIPK2 propagates signaling primarily as a scaffold rather than a catalyst: K63-linked polyubiquitination recruits TAK1 to activate the IKK complex [PMID:18079694], and the interaction between RIPK2 and the E3 ligase XIAP—mediated by the β2-β3 loop of the kinase N-lobe adjacent to the ATP pocket—is mechanistically more important than catalytic activity for productive NOD signaling, explaining why ATP-competitive and type II kinase inhibitors act largely by sterically blocking the RIPK2-XIAP interface [PMID:30026309, PMID:26320862]. RIPK2 also undergoes autophosphorylation at Y474 and S176 that governs assembly of higher-order detergent-insoluble speck-like complexes, a process restrained by XIAP-mediated ubiquitination [PMID:31350258]. The pathway connects upstream to oligomerization-induced NF-κB activation via the intermediate region and IKKγ/NEMO [PMID:10880512], and RIPK2 additionally operates downstream of TLR2/3/4 and IL-1/IL-18 receptors and in T-cell receptor signaling required for IL-2 production and TH1 differentiation [PMID:11894098]. RIPK2 abundance and activity are tuned by an opposing set of writers and erasers acting on its ubiquitination and phosphorylation—including K48-ubiquitin control of stability, the deubiquitinases YOD1 and MYSM1, and the K63-promoting ligase-associated factor N4BP3 [PMID:32954645, PMID:39333628, PMID:39746943, PMID:39420190]—and the kinase is targeted for inactivation by pathogen-derived enzymes including Yersinia YopJ acetylation of its activation loop and gingipain (Kgp) proteolysis [PMID:22520462, PMID:22685397]. Beyond canonical innate immunity, RIPK2 drives cancer metastasis through a noncanonical pathway in which it binds and activates MKK7 to stabilize c-Myc [PMID:35115556].","teleology":[{"year":1998,"claim":"Established RIPK2's basic architecture and first signaling outputs, framing it as a CARD-containing kinase linking death/inflammatory adaptors to NF-κB, JNK, and caspase activation.","evidence":"Co-IP, overexpression, dominant-negative K38M mutagenesis, and NF-κB/JNK reporter and apoptosis assays identifying interactions with CLARP/caspase-8, caspase-1, and TRAFs","pmids":["9575181","9705938"],"confidence":"High","gaps":["Overexpression-based; physiological receptor context not yet defined","Whether kinase activity or scaffolding drives each output unresolved"]},{"year":2000,"claim":"Defined an induced-proximity model whereby RIPK2 oligomerization engages IKKγ/NEMO through its intermediate region, not its kinase domain, to activate NF-κB downstream of NOD1.","evidence":"Co-IP, enforced oligomerization, dominant-negative IKKγ, and NF-κB reporter assays","pmids":["10880512"],"confidence":"High","gaps":["How endogenous receptor engagement triggers oligomerization not shown","Role of ubiquitination in IKK recruitment not yet addressed"]},{"year":2002,"claim":"Genetically placed RIPK2 downstream of multiple immune receptors, showing it is required for innate responses (TLR2/3/4, NOD, IL-1/IL-18) and adaptive T-cell function.","evidence":"Rip2-deficient mouse cells with recruitment Co-IP, cytokine, NF-κB, T-cell proliferation and TH1 differentiation readouts","pmids":["11894098"],"confidence":"High","gaps":["Breadth of TLR involvement later narrowed by cleaner agonist studies","Direct versus indirect roles in adaptive immunity not fully separated"]},{"year":2005,"claim":"Provided in vitro enzymatic characterization, identifying substrates and the residue conferring pyridinyl imidazole inhibitor sensitivity.","evidence":"In vitro autophosphorylation and substrate (MBP, histone H3) kinase assays with Km determination and conserved threonine mutant analysis","pmids":["15724446"],"confidence":"High","gaps":["Physiological relevance of MBP/H3 as substrates unestablished","In vitro substrates may not reflect in-cell targets"]},{"year":2006,"claim":"Resolved the structural basis of NOD1-RIPK2 CARD-CARD recognition, identifying the electrostatic interface essential for downstream signaling.","evidence":"NMR structure of NOD1 CARD with mutagenesis of acidic/basic residue pairs, Co-IP, and NF-κB reporter validation","pmids":["17054981"],"confidence":"High","gaps":["NOD2 CARD interface not structurally resolved here","Affinity and stoichiometry of the assembled complex not quantified"]},{"year":2007,"claim":"Defined the central signaling steps: clean genetic placement downstream of NOD1/NOD2, K63-ubiquitination at K209 recruiting TAK1, and NOD2-driven membrane recruitment as the site of optimal signaling.","evidence":"RICK-null macrophages, K209 mutagenesis and ubiquitination assays with TAK1-deficient cells, and membrane-targeting/fractionation constructs including the NOD2 1007FS mutant","pmids":["17277144","18079694","17355968"],"confidence":"High","gaps":["K209 ubiquitination later not detected at endogenous levels","E3 ligase responsible for K63 chains not identified at this stage"]},{"year":2012,"claim":"Revealed RIPK2 as a target of bacterial immune-evasion enzymes that inactivate it by distinct mechanisms.","evidence":"In-cell acetylation assay with catalytically dead YopJ control, and cell-free proteolysis with Kgp-specific inhibitor and isogenic Kgp-deficient P. gingivalis","pmids":["22520462","22685397"],"confidence":"High","gaps":["RIPK2 acetylation and cleavage sites not fully mapped","Consequences for higher-order complex assembly not examined"]},{"year":2015,"claim":"Dissected the kinase-activity-versus-scaffold question with structures and selective inhibitors, showing type II inhibitors block autophosphorylation, ubiquitination, and NF-κB signaling while kinase activity timing tunes productive responses.","evidence":"First RIPK2 crystal structure with ponatinib, type I vs type II inhibitor profiling, and the selective inhibitor WEHI-345 with ubiquitylation kinetics and in vivo/EAE readouts","pmids":["26320862","25778803"],"confidence":"High","gaps":["Molecular reason inhibitors block ubiquitination not yet defined (resolved later)","Distinction between catalytic and non-catalytic inhibitor effects unresolved here"]},{"year":2015,"claim":"Extended the proteolytic-inactivation theme to viral infection, implicating HIV-1 protease cleavage of RIPK2 as a candidate immune-evasion strategy.","evidence":"HIV-1 infection of T cells with stage-specific protease/RT/integrase inhibitors and Co-IP of the related RIPK1/RIPK3 complex","pmids":["26297639"],"confidence":"Medium","gaps":["RIPK2 cleavage site not mapped","Functional consequence for RIPK2 signaling not directly demonstrated"]},{"year":2018,"claim":"Resolved the inhibitor mechanism by mapping the XIAP-binding site to the β2-β3 loop near the ATP pocket, establishing that inhibitors act by blocking the RIPK2-XIAP interaction rather than catalysis.","evidence":"XIAP binding mapping, site-directed mutagenesis, kinase assays, Co-IP, and in vivo NOD2 signaling, plus a co-crystal structure of RIPK2 with the activation-loop inhibitor CSR35 defining a Lys169 ionic contact","pmids":["30026309","29409752"],"confidence":"High","gaps":["Stoichiometry and dynamics of the RIPK2-XIAP complex not fully defined","How XIAP ubiquitination is coupled to TAK1/IKK recruitment not fully resolved"]},{"year":2019,"claim":"Connected RIPK2 autophosphorylation to higher-order assembly, showing Y474/S176 phosphorylation drives speck-like complex formation that XIAP-mediated ubiquitination restrains.","evidence":"Detergent fractionation with Y474/S176 and XIAP-ubiquitylation-site mutagenesis in bacterial infection models","pmids":["31350258"],"confidence":"High","gaps":["Functional output of speck assembly versus signaling not fully separated","Structure of the higher-order complex unknown"]},{"year":2020,"claim":"Refined the ubiquitin code at endogenous levels, distinguishing K48 control of stability from a separate XIAP-binding regulatory region, and identifying the MYSM1-PP2A axis as an eraser of RIPK2 ubiquitination and S176 phosphorylation.","evidence":"CRISPR FLAG-RIPK2 knock-in mice with MS-based PTM mapping and mutagenesis; MYSM1-PP2A-RIPK2 Co-IP with S176 phosphomimetic/phospho-dead mutants in an OA model","pmids":["32954645","39746943"],"confidence":"High","gaps":["Identity of the K48 ligase(s) controlling stability not pinned down","Reconciliation with prior K209 ubiquitination model only partially addressed"]},{"year":2022,"claim":"Defined a noncanonical, oncogenic RIPK2 pathway in which it binds and activates MKK7 to phosphorylate and stabilize c-Myc, driving metastasis independent of NOD/NF-κB.","evidence":"Co-IP, multi-level proteomics, RIPK2 knockout, c-Myc-S62 phosphorylation assays, inhibitors, and in vivo metastasis models","pmids":["35115556"],"confidence":"High","gaps":["How RIPK2 selects MKK7 over canonical effectors not defined","Relationship between scaffolding and catalytic requirements in this pathway unclear"]},{"year":2024,"claim":"Expanded the network of opposing ubiquitin enzymes tuning RIPK2 abundance and activity, with YOD1 protecting RIPK2 from K48-degradation and N4BP3 promoting activating K63 chains.","evidence":"YOD1-deficient mice with K48-linkage assays and DSS colitis; N4BP3 Co-IP, K63-ubiquitination assays, siRNA knockdown, and phosphoprotein readouts","pmids":["39333628","39420190"],"confidence":"Medium","gaps":["Direct enzyme-substrate kinetics not established for N4BP3","Whether YOD1 and XIAP act on overlapping sites unknown"]},{"year":null,"claim":"How RIPK2's canonical scaffolding/ubiquitination machinery is repurposed in its noncanonical oncogenic and inflammasome-modulating roles, and how the full set of writer/eraser enzymes is coordinated in vivo, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM state to choice between NOD/NF-κB, MKK7/c-Myc, and caspase-1 modulation","Structure of the assembled NOD-RIPK2-XIAP-TAK1 signaling node not determined","Relative in vivo contribution of catalytic versus scaffold functions across tissues unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[19,17,23]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[19,0,6]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,6,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,3,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,17,27]}],"complexes":[],"partners":["NOD1","NOD2","XIAP","TAK1","IKBKG","TRAF6","MAP2K7","PRKCI"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43353","full_name":"Receptor-interacting serine/threonine-protein kinase 2","aliases":["CARD-containing interleukin-1 beta-converting enzyme-associated kinase","CARD-containing IL-1 beta ICE-kinase","RIP-like-interacting CLARP kinase","Receptor-interacting protein 2","RIP-2","Tyrosine-protein kinase RIPK2"],"length_aa":540,"mass_kda":61.2,"function":"Serine/threonine/tyrosine-protein kinase that plays an essential role in modulation of innate and adaptive immune responses (PubMed:14638696, PubMed:17054981, PubMed:21123652, PubMed:28656966, PubMed:9575181, PubMed:9642260). Acts as a key effector of NOD1 and NOD2 signaling pathways: upon activation by bacterial peptidoglycans, NOD1 and NOD2 oligomerize and recruit RIPK2 via CARD-CARD domains, leading to the formation of RIPK2 filaments (PubMed:17054981, PubMed:17562858, PubMed:21123652, PubMed:22607974, PubMed:28656966, PubMed:29452636, PubMed:30026309). Once recruited, RIPK2 autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3, as well as 'Met-1'-linked (linear) polyubiquitination by the LUBAC complex, becoming a scaffolding protein for downstream effectors (PubMed:22607974, PubMed:28545134, PubMed:29452636, PubMed:30026309, PubMed:30279485, PubMed:30478312). 'Met-1'-linked polyubiquitin chains attached to RIPK2 recruit IKBKG/NEMO, which undergoes 'Lys-63'-linked polyubiquitination in a RIPK2-dependent process (PubMed:17562858, PubMed:22607974, PubMed:29452636, PubMed:30026309). 'Lys-63'-linked polyubiquitin chains attached to RIPK2 serve as docking sites for TAB2 and TAB3 and mediate the recruitment of MAP3K7/TAK1 to IKBKG/NEMO, inducing subsequent activation of IKBKB/IKKB (PubMed:18079694). In turn, NF-kappa-B is released from NF-kappa-B inhibitors and translocates into the nucleus where it activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis (PubMed:18079694). The protein kinase activity is dispensable for the NOD1 and NOD2 signaling pathways (PubMed:29452636, PubMed:30026309). Contributes to the tyrosine phosphorylation of the guanine exchange factor ARHGEF2 through Src tyrosine kinase leading to NF-kappa-B activation by NOD2 (PubMed:21887730). Also involved in adaptive immunity: plays a role during engagement of the T-cell receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-kappa-B activation (PubMed:14638696). Plays a role in the inactivation of RHOA in response to NGFR signaling (PubMed:26646181)","subcellular_location":"Cytoplasm; Cell membrane; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/O43353/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RIPK2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RIPK2","total_profiled":1310},"omim":[{"mim_id":"615806","title":"SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 4; SLC15A4","url":"https://www.omim.org/entry/615806"},{"mim_id":"615680","title":"CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 16; CARD16","url":"https://www.omim.org/entry/615680"},{"mim_id":"613407","title":"LEPROSY, SUSCEPTIBILITY TO, 6; LPRS6","url":"https://www.omim.org/entry/613407"},{"mim_id":"610767","title":"AUTOPHAGY 16-LIKE 1; ATG16L1","url":"https://www.omim.org/entry/610767"},{"mim_id":"610408","title":"SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 3; SLC15A3","url":"https://www.omim.org/entry/610408"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RIPK2"},"hgnc":{"alias_symbol":["RICK","RIP2","CARDIAK","CARD3"],"prev_symbol":[]},"alphafold":{"accession":"O43353","domains":[{"cath_id":"3.30.200.20","chopping":"16-97","consensus_level":"high","plddt":88.54,"start":16,"end":97},{"cath_id":"1.10.510.10","chopping":"102-174_192-197_207-302","consensus_level":"high","plddt":92.7946,"start":102,"end":302},{"cath_id":"1.10.533.10","chopping":"436-518","consensus_level":"high","plddt":92.5155,"start":436,"end":518}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43353","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43353-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43353-F1-predicted_aligned_error_v6.png","plddt_mean":76.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RIPK2","jax_strain_url":"https://www.jax.org/strain/search?query=RIPK2"},"sequence":{"accession":"O43353","fasta_url":"https://rest.uniprot.org/uniprotkb/O43353.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43353/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43353"}},"corpus_meta":[{"pmid":"11894098","id":"PMC_11894098","title":"RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11894098","citation_count":727,"is_preprint":false},{"pmid":"10880512","id":"PMC_10880512","title":"An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10880512","citation_count":444,"is_preprint":false},{"pmid":"18079694","id":"PMC_18079694","title":"A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18079694","citation_count":430,"is_preprint":false},{"pmid":"17277144","id":"PMC_17277144","title":"RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17277144","citation_count":426,"is_preprint":false},{"pmid":"9705938","id":"PMC_9705938","title":"Identification of CARDIAK, a RIP-like kinase that associates with caspase-1.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9705938","citation_count":269,"is_preprint":false},{"pmid":"9575181","id":"PMC_9575181","title":"RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9575181","citation_count":217,"is_preprint":false},{"pmid":"15289440","id":"PMC_15289440","title":"Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease.","date":"2004","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15289440","citation_count":194,"is_preprint":false},{"pmid":"32198438","id":"PMC_32198438","title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32198438","citation_count":177,"is_preprint":false},{"pmid":"17579072","id":"PMC_17579072","title":"Nod1/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17579072","citation_count":154,"is_preprint":false},{"pmid":"31903123","id":"PMC_31903123","title":"Fusobacterium nucleatum Promotes Metastasis in Colorectal Cancer by Activating Autophagy Signaling via the Upregulation of CARD3 Expression.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31903123","citation_count":152,"is_preprint":false},{"pmid":"15691843","id":"PMC_15691843","title":"Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15691843","citation_count":130,"is_preprint":false},{"pmid":"25778803","id":"PMC_25778803","title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25778803","citation_count":115,"is_preprint":false},{"pmid":"22520462","id":"PMC_22520462","title":"Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction.","date":"2012","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/22520462","citation_count":109,"is_preprint":false},{"pmid":"17355968","id":"PMC_17355968","title":"The NOD2-RICK complex signals from the plasma membrane.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17355968","citation_count":98,"is_preprint":false},{"pmid":"35033591","id":"PMC_35033591","title":"Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35033591","citation_count":97,"is_preprint":false},{"pmid":"26320862","id":"PMC_26320862","title":"Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/26320862","citation_count":90,"is_preprint":false},{"pmid":"25213858","id":"PMC_25213858","title":"In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25213858","citation_count":88,"is_preprint":false},{"pmid":"31610014","id":"PMC_31610014","title":"Fusobacterium nucleatum facilitates ulcerative colitis through activating IL-17F signaling to NF-κB via the upregulation of CARD3 expression.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31610014","citation_count":84,"is_preprint":false},{"pmid":"18549453","id":"PMC_18549453","title":"The TLR2-MyD88-NOD2-RIPK2 signalling axis regulates a balanced pro-inflammatory and IL-10-mediated anti-inflammatory cytokine response to Gram-positive cell walls.","date":"2008","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18549453","citation_count":82,"is_preprint":false},{"pmid":"24670424","id":"PMC_24670424","title":"NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24670424","citation_count":72,"is_preprint":false},{"pmid":"33935757","id":"PMC_33935757","title":"RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33935757","citation_count":65,"is_preprint":false},{"pmid":"31132297","id":"PMC_31132297","title":"RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.","date":"2019","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31132297","citation_count":64,"is_preprint":false},{"pmid":"17054981","id":"PMC_17054981","title":"Solution structure of NOD1 CARD and mutational analysis of its interaction with the CARD of downstream kinase RICK.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17054981","citation_count":64,"is_preprint":false},{"pmid":"12775719","id":"PMC_12775719","title":"CARD6 is a modulator of NF-kappa B activation by Nod1- and Cardiak-mediated pathways.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12775719","citation_count":61,"is_preprint":false},{"pmid":"15724446","id":"PMC_15724446","title":"Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.","date":"2005","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15724446","citation_count":60,"is_preprint":false},{"pmid":"30026309","id":"PMC_30026309","title":"Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30026309","citation_count":60,"is_preprint":false},{"pmid":"24927559","id":"PMC_24927559","title":"Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2-/- (TRUC) mice.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24927559","citation_count":60,"is_preprint":false},{"pmid":"34432979","id":"PMC_34432979","title":"Optimization of a Series of RIPK2 PROTACs.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34432979","citation_count":54,"is_preprint":false},{"pmid":"28799230","id":"PMC_28799230","title":"Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways.","date":"2017","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28799230","citation_count":53,"is_preprint":false},{"pmid":"32101030","id":"PMC_32101030","title":"Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.","date":"2020","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32101030","citation_count":49,"is_preprint":false},{"pmid":"33633788","id":"PMC_33633788","title":"Knockdown of RIPK2 Inhibits Proliferation and Migration, and Induces Apoptosis via the NF-κB Signaling Pathway in Gastric Cancer.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33633788","citation_count":47,"is_preprint":false},{"pmid":"35998069","id":"PMC_35998069","title":"Fusobacterium nucleatum Extracellular Vesicles Promote Experimental Colitis by Modulating Autophagy via the miR-574-5p/CARD3 Axis.","date":"2023","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35998069","citation_count":45,"is_preprint":false},{"pmid":"15528195","id":"PMC_15528195","title":"A role for rat inositol polyphosphate kinases rIPK2 and rIPK1 in inositol pentakisphosphate and inositol hexakisphosphate production in rat-1 cells.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15528195","citation_count":44,"is_preprint":false},{"pmid":"32631784","id":"PMC_32631784","title":"RIPK2 NODs to XIAP and IBD.","date":"2020","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32631784","citation_count":43,"is_preprint":false},{"pmid":"32153411","id":"PMC_32153411","title":"Fusobacterium nucleatum Activates Endoplasmic Reticulum Stress to Promote Crohn's Disease Development via the Upregulation of CARD3 Expression.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32153411","citation_count":43,"is_preprint":false},{"pmid":"24015287","id":"PMC_24015287","title":"LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24015287","citation_count":41,"is_preprint":false},{"pmid":"29057049","id":"PMC_29057049","title":"Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.","date":"2017","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/29057049","citation_count":40,"is_preprint":false},{"pmid":"22491249","id":"PMC_22491249","title":"Joint NOD2/RIPK2 signaling regulates IL-17 axis and contributes to the development of experimental arthritis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22491249","citation_count":40,"is_preprint":false},{"pmid":"35115556","id":"PMC_35115556","title":"Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35115556","citation_count":39,"is_preprint":false},{"pmid":"22685397","id":"PMC_22685397","title":"Pathogen-mediated proteolysis of the cell death regulator RIPK1 and the host defense modulator RIPK2 in human aortic endothelial cells.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22685397","citation_count":35,"is_preprint":false},{"pmid":"27169686","id":"PMC_27169686","title":"High Glucose and Lipopolysaccharide Activate NOD1- RICK-NF-κB Inflammatory Signaling in Mesangial Cells.","date":"2016","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/27169686","citation_count":33,"is_preprint":false},{"pmid":"32349637","id":"PMC_32349637","title":"CARD3 Promotes Cerebral Ischemia-Reperfusion Injury Via Activation of TAK1.","date":"2020","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/32349637","citation_count":32,"is_preprint":false},{"pmid":"28484277","id":"PMC_28484277","title":"Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28484277","citation_count":32,"is_preprint":false},{"pmid":"26297639","id":"PMC_26297639","title":"HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2.","date":"2015","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/26297639","citation_count":31,"is_preprint":false},{"pmid":"14670961","id":"PMC_14670961","title":"RICK activates a NF-kappaB-dependent anti-human cytomegalovirus response.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14670961","citation_count":30,"is_preprint":false},{"pmid":"29874851","id":"PMC_29874851","title":"RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis.","date":"2018","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/29874851","citation_count":30,"is_preprint":false},{"pmid":"37777791","id":"PMC_37777791","title":"Receptor-interacting protein kinase 2 (RIPK2) profoundly contributes to post-stroke neuroinflammation and behavioral deficits with microglia as unique perpetrators.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37777791","citation_count":28,"is_preprint":false},{"pmid":"31350258","id":"PMC_31350258","title":"XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures.","date":"2019","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/31350258","citation_count":26,"is_preprint":false},{"pmid":"36959850","id":"PMC_36959850","title":"Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36959850","citation_count":25,"is_preprint":false},{"pmid":"32909611","id":"PMC_32909611","title":"ATG16L1 negatively regulates RICK/RIP2-mediated innate immune responses.","date":"2021","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32909611","citation_count":25,"is_preprint":false},{"pmid":"31485193","id":"PMC_31485193","title":"RIPK2-Mediated Autophagy and Negatively Regulated ROS-NLRP3 Inflammasome Signaling in GMCs Stimulated with High Glucose.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31485193","citation_count":25,"is_preprint":false},{"pmid":"37324457","id":"PMC_37324457","title":"RIPK2: a promising target for cancer treatment.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37324457","citation_count":23,"is_preprint":false},{"pmid":"32634524","id":"PMC_32634524","title":"NLRC3-like 1 inhibits NOD1-RIPK2 pathway via targeting RIPK2.","date":"2020","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32634524","citation_count":23,"is_preprint":false},{"pmid":"35732460","id":"PMC_35732460","title":"NOD/RIPK2 signalling pathway contributes to osteoarthritis susceptibility.","date":"2022","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35732460","citation_count":23,"is_preprint":false},{"pmid":"26202066","id":"PMC_26202066","title":"Expression and activity of NOD1 and NOD2/RIPK2 signalling in mononuclear cells from patients with rheumatoid arthritis.","date":"2015","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/26202066","citation_count":23,"is_preprint":false},{"pmid":"23321697","id":"PMC_23321697","title":"CARD3 deficiency exacerbates diet-induced obesity, hepatosteatosis, and insulin resistance in male mice.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23321697","citation_count":22,"is_preprint":false},{"pmid":"21931826","id":"PMC_21931826","title":"Cigarette smoke extract (CSE) delays NOD2 expression and affects NOD2/RIPK2 interactions in intestinal epithelial cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21931826","citation_count":21,"is_preprint":false},{"pmid":"24625812","id":"PMC_24625812","title":"NOD2/RICK-dependent β-defensin 2 regulation is protective for nontypeable Haemophilus influenzae-induced middle ear infection.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24625812","citation_count":21,"is_preprint":false},{"pmid":"26463597","id":"PMC_26463597","title":"Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction.","date":"2015","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26463597","citation_count":20,"is_preprint":false},{"pmid":"32473019","id":"PMC_32473019","title":"RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32473019","citation_count":20,"is_preprint":false},{"pmid":"25917637","id":"PMC_25917637","title":"NOD2 pathway via RIPK2 and TBK1 is involved in the aberrant catabolism induced by T-2 toxin in chondrocytes.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/25917637","citation_count":20,"is_preprint":false},{"pmid":"16582588","id":"PMC_16582588","title":"CARD tricks: controlling the interactions of CARD6 with RICK and microtubules.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16582588","citation_count":19,"is_preprint":false},{"pmid":"35709396","id":"PMC_35709396","title":"Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35709396","citation_count":19,"is_preprint":false},{"pmid":"34825931","id":"PMC_34825931","title":"Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway.","date":"2021","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34825931","citation_count":19,"is_preprint":false},{"pmid":"29659823","id":"PMC_29659823","title":"A hyperactivating proinflammatory RIPK2 allele associated with early-onset osteoarthritis.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29659823","citation_count":19,"is_preprint":false},{"pmid":"19188356","id":"PMC_19188356","title":"RICK promotes inflammation and lethality after gram-negative bacterial infection in mice stimulated with lipopolysaccharide.","date":"2009","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19188356","citation_count":19,"is_preprint":false},{"pmid":"29409752","id":"PMC_29409752","title":"Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.","date":"2018","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/29409752","citation_count":18,"is_preprint":false},{"pmid":"37016317","id":"PMC_37016317","title":"Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37016317","citation_count":17,"is_preprint":false},{"pmid":"37023697","id":"PMC_37023697","title":"RIPK2 as a promising druggable target for autoimmune diseases.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37023697","citation_count":16,"is_preprint":false},{"pmid":"32505849","id":"PMC_32505849","title":"Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32505849","citation_count":16,"is_preprint":false},{"pmid":"35618701","id":"PMC_35618701","title":"Card9 protects sepsis by regulating Ripk2-mediated activation of NLRP3 inflammasome in macrophages.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35618701","citation_count":16,"is_preprint":false},{"pmid":"34494462","id":"PMC_34494462","title":"The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.","date":"2021","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34494462","citation_count":16,"is_preprint":false},{"pmid":"33868233","id":"PMC_33868233","title":"microRNA-210 and microRNA-3570 Negatively Regulate NF-κB-Mediated Inflammatory Responses by Targeting RIPK2 in Teleost Fish.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33868233","citation_count":16,"is_preprint":false},{"pmid":"37531744","id":"PMC_37531744","title":"RIPK2 inhibitors for disease therapy: Current status and perspectives.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37531744","citation_count":15,"is_preprint":false},{"pmid":"12755636","id":"PMC_12755636","title":"Equilibrium and kinetic folding of an alpha-helical Greek key protein domain: caspase recruitment domain (CARD) of RICK.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12755636","citation_count":14,"is_preprint":false},{"pmid":"22484241","id":"PMC_22484241","title":"The anti-inflammatory actions of IL-4 in human monocytes are not mediated by IL-10, RP105 or the kinase activity of RIPK2.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22484241","citation_count":14,"is_preprint":false},{"pmid":"37306596","id":"PMC_37306596","title":"Characterization of the Inflammatory Response Evoked by Bacterial Membrane Vesicles in Intestinal Cells Reveals an RIPK2-Dependent Activation by Enterotoxigenic Escherichia coli Vesicles.","date":"2023","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/37306596","citation_count":14,"is_preprint":false},{"pmid":"39420190","id":"PMC_39420190","title":"N4BP3 facilitates NOD2-MAPK/NF-κB pathway in inflammatory bowel disease through mediating K63-linked RIPK2 ubiquitination.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39420190","citation_count":13,"is_preprint":false},{"pmid":"33601309","id":"PMC_33601309","title":"Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33601309","citation_count":13,"is_preprint":false},{"pmid":"32954645","id":"PMC_32954645","title":"A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32954645","citation_count":13,"is_preprint":false},{"pmid":"23952047","id":"PMC_23952047","title":"RIP2/RICK-dependent cytokine production upon Yersinia enterocolitica infection in macrophages with TLR4 deficiency.","date":"2013","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23952047","citation_count":13,"is_preprint":false},{"pmid":"26500656","id":"PMC_26500656","title":"Dysfunctional Crohn's Disease-Associated NOD2 Polymorphisms Cannot be Reliably Predicted on the Basis of RIPK2 Binding or Membrane Association.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26500656","citation_count":13,"is_preprint":false},{"pmid":"37315817","id":"PMC_37315817","title":"Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37315817","citation_count":12,"is_preprint":false},{"pmid":"24169446","id":"PMC_24169446","title":"Activation of NOD2/RIPK2 pathway induces mitochondrial injury to oligodendrocyte precursor cells in vitro and CNS demyelination in vivo.","date":"2013","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/24169446","citation_count":12,"is_preprint":false},{"pmid":"37211186","id":"PMC_37211186","title":"RIPK2 promotes the progression of colon cancer by regulating BIRC3-mediated ubiquitination of IKBKG.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37211186","citation_count":11,"is_preprint":false},{"pmid":"25742400","id":"PMC_25742400","title":"CARD3 deficiency protects against colitis through reduced epithelial cell apoptosis.","date":"2015","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25742400","citation_count":9,"is_preprint":false},{"pmid":"35477477","id":"PMC_35477477","title":"High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.","date":"2022","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/35477477","citation_count":9,"is_preprint":false},{"pmid":"35473583","id":"PMC_35473583","title":"A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours.","date":"2022","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35473583","citation_count":9,"is_preprint":false},{"pmid":"26040030","id":"PMC_26040030","title":"The expression of CCN2, IQSEC, RSPO1, DNAJC15, RIPK2, IL13RA2, IRS1, and IRS2 genes in blood of obese boys with insulin resistance.","date":"2015","source":"Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/26040030","citation_count":9,"is_preprint":false},{"pmid":"22314416","id":"PMC_22314416","title":"The RIPK2 gene: a positional candidate for tick burden supported by genetic associations in cattle and immunological response of knockout mouse.","date":"2012","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22314416","citation_count":9,"is_preprint":false},{"pmid":"40406369","id":"PMC_40406369","title":"Current advances on RIPK2 and its inhibitors in pathological processes: a comprehensive review.","date":"2025","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/40406369","citation_count":8,"is_preprint":false},{"pmid":"39746943","id":"PMC_39746943","title":"MYSM1 attenuates osteoarthritis by recruiting PP2A to deubiquitinate and dephosphorylate RIPK2.","date":"2025","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/39746943","citation_count":8,"is_preprint":false},{"pmid":"16501221","id":"PMC_16501221","title":"Substitutions of prolines examine their role in kinetic trap formation of the caspase recruitment domain (CARD) of RICK.","date":"2006","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/16501221","citation_count":8,"is_preprint":false},{"pmid":"39333628","id":"PMC_39333628","title":"YOD1 sustains NOD2-mediated protective signaling in colitis by stabilizing RIPK2.","date":"2024","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/39333628","citation_count":7,"is_preprint":false},{"pmid":"26466644","id":"PMC_26466644","title":"The immunomodulatory effects of barettin and involvement of the kinases CAMK1α and RIPK2.","date":"2015","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26466644","citation_count":7,"is_preprint":false},{"pmid":"33169892","id":"PMC_33169892","title":"RICK regulates the odontogenic differentiation of dental pulp stem cells through activation of TNF-α via the ERK and not through NF-κB signaling pathway.","date":"2021","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/33169892","citation_count":7,"is_preprint":false},{"pmid":"38174135","id":"PMC_38174135","title":"A Look at Spinal Cord Injury in Canada: Rick Hansen Spinal Cord Injury Registry (RHSCIR) - 2021 SCI Data Summary.","date":"2023","source":"Topics in spinal cord injury rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/38174135","citation_count":7,"is_preprint":false},{"pmid":"40185717","id":"PMC_40185717","title":"RIPK2 promotes colorectal cancer metastasis by protecting YAP degradation from ITCH-mediated ubiquitination.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40185717","citation_count":6,"is_preprint":false},{"pmid":"38729551","id":"PMC_38729551","title":"Pharmacological inhibition of receptor-interacting protein kinase 2 (RIPK2) elicits neuroprotective effects following experimental ischemic stroke.","date":"2024","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38729551","citation_count":6,"is_preprint":false},{"pmid":"36408835","id":"PMC_36408835","title":"Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.","date":"2023","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36408835","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51402,"output_tokens":9101,"usd":0.145361,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19117,"output_tokens":5289,"usd":0.113905,"stage2_stop_reason":"end_turn"},"total_usd":0.259266,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"RICK (RIPK2) was identified as a novel serine-threonine kinase containing an N-terminal kinase domain and C-terminal CARD. It physically interacts with CLARP (a caspase-like molecule binding FADD and caspase-8), and its expression promoted caspase-8 activation and apoptosis induced by Fas ligand, FADD, and caspase-8. A kinase-dead mutant (K38M) functioned as a dominant-negative inhibitor of CD95-mediated apoptosis, demonstrating both kinase domain and CARD are required for pro-apoptotic function.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, dominant-negative mutagenesis, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding demonstrated, mutagenesis of ATP-binding site, multiple functional readouts in a single study\",\n      \"pmids\": [\"9575181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CARDIAK (RIPK2) was identified as a RIP-like kinase containing a CARD that specifically interacts with caspase-1 via CARD-CARD interaction. This interaction correlated with processing of pro-caspase-1 to the active p20 subunit. Overexpression activated both NF-κB and JNK, and CARDIAK interacted with TRAF-1 and TRAF-2; dominant-negative TRAF-2 inhibited CARDIAK-induced NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, NF-κB/JNK reporter assays, dominant-negative TRAF-2\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple binding partners identified by Co-IP, functional NF-κB and JNK activation assays, caspase-1 processing demonstrated\",\n      \"pmids\": [\"9705938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RICK (RIPK2) was shown to interact with IKKγ (NEMO) via its intermediate region (not its kinase domain), linking NOD1/Nod1-mediated proximity signaling to IKK activation. Enforced oligomerization of RICK was sufficient to activate NF-κB, and a mutant IKKγ deficient in IKKα/β binding blocked RICK-induced NF-κB activation. This defined an induced-proximity model for NF-κB activation downstream of Nod1.\",\n      \"method\": \"Co-immunoprecipitation, enforced oligomerization, dominant-negative IKKγ, NF-κB reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, forced oligomerization, dominant-negative), mechanistic pathway placement established\",\n      \"pmids\": [\"10880512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rip2 (RIPK2) was recruited to TLR2 signaling complexes after ligand stimulation. Rip2-deficient cells showed reduced cytokine production upon TLR2/3/4 stimulation but not TLR9, indicating Rip2 acts downstream of TLR2/3/4 but not TLR9. Rip2-deficient cells were also hyporesponsive to IL-1 and IL-18 receptor signaling and to Nod proteins. Rip2-deficient T cells showed severely reduced NF-κB activation, IL-2 production, proliferation on TCR engagement, and impaired TH1 differentiation.\",\n      \"method\": \"Rip2-deficient mouse cells, co-immunoprecipitation (recruitment to TLR2 complex), cytokine assays, NF-κB activation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout combined with Co-IP recruitment assay and multiple functional readouts across innate and adaptive immunity\",\n      \"pmids\": [\"11894098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NMR solution structure of the NOD1 CARD was determined. Mutagenesis revealed that CARD-CARD interaction between NOD1 and RICK is critically dependent on three acidic residues on NOD1 CARD and three basic residues on RICK CARD, indicating a strong electrostatic component to the NOD1-RICK interaction essential for downstream NF-κB signaling.\",\n      \"method\": \"NMR structure determination, site-directed mutagenesis, co-immunoprecipitation from cell lysates, NF-κB reporter assay\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure combined with mutagenesis and functional NF-κB validation; mechanistic interface defined\",\n      \"pmids\": [\"17054981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RICK (RIPK2) is required for innate immune responses to Nod1 and Nod2 agonists but not for responses to highly purified TLR agonists (LPS, etc.) in macrophages and mice. RICK-null macrophages were defective in Nod1/Nod2-mediated NF-κB activation and cytokine production, while TLR-mediated responses were intact. This definitively placed RICK downstream of Nod1/Nod2 but not TLRs.\",\n      \"method\": \"RICK-deficient mouse macrophages, cytokine ELISA, NF-κB activation assays, in vivo infection models\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with clean pathway placement, multiple agonists tested, both in vitro and in vivo, independently confirmed by multiple labs\",\n      \"pmids\": [\"17277144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RICK undergoes K63-linked polyubiquitination at lysine 209 (K209) in its kinase domain upon Nod1 or Nod2 stimulation or RICK oligomerization. This ubiquitination is essential for IKK activation and cytokine/chemokine secretion but does not require RICK kinase activity or alter RICK-NEMO interaction. K63-polyubiquitinated RICK recruits TAK1, linking TAK1 to IKK complexes as a critical step in Nod-mediated NF-κB activation.\",\n      \"method\": \"Ubiquitination assays, K209 mutagenesis, co-immunoprecipitation, cytokine secretion assays, TAK1-deficient cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-specific mutagenesis (K209), in-cell ubiquitination assays, genetic (TAK1-deficient cells) and biochemical validation of TAK1 recruitment\",\n      \"pmids\": [\"18079694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NOD2 promotes the membrane recruitment of RICK; membrane-anchored NOD2 recruits RICK to the plasma membrane where RICK signaling is optimal. Artificial attachment of RICK at the plasma membrane caused constitutive strong NF-κB activation and IL-8 secretion. The NOD2 1007FS Crohn's disease mutant was unable to signal from the plasma membrane, correlating with impaired RICK recruitment.\",\n      \"method\": \"Subcellular fractionation, membrane targeting constructs, immunofluorescence, NF-κB reporter assays, IL-8 secretion measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiments with functional consequence, artificial membrane targeting with constitutive activation, disease-relevant mutant analysis\",\n      \"pmids\": [\"17355968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The Yersinia pseudotuberculosis effector YopJ acetylates critical sites in the activation loops of RICK and TAK1 kinases, blocking their activity. The catalytically inactive YopJ(C172A) mutant failed to acetylate RICK or TAK1 and could not subvert Nod2 signaling. YopJ acetylation of RICK also decreased the affinity of Nod2 for RICK and concurrently redirected Nod2 to interact with and activate caspase-1.\",\n      \"method\": \"In-cell acetylation assay, catalytically inactive mutant YopJ, co-immunoprecipitation, caspase-1 activation assay, IL-1β measurement\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic modification (acetylation) demonstrated with catalytically inactive control, multiple orthogonal readouts\",\n      \"pmids\": [\"22520462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"P. gingivalis infection of human aortic endothelial cells caused rapid cleavage of RIPK2. Cleavage was not observed with apoptotic stimuli or TLR/NOD agonists, was inhibited by a lysine-specific gingipain (Kgp) inhibitor, and was absent with an isogenic Kgp-deficient P. gingivalis mutant. Direct proteolysis of RIPK2 by P. gingivalis was confirmed in a cell-free system, defining Kgp as the protease responsible.\",\n      \"method\": \"Cell-free proteolysis assay, Kgp-specific inhibitor, isogenic Kgp-deficient mutant, immunoblotting\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-free reconstitution of proteolysis, isogenic mutant control, specific inhibitor, multiple orthogonal validations\",\n      \"pmids\": [\"22685397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RIPK2 kinase activity is dispensable for NF-κB activation per se, but type II kinase inhibitors (ponatinib, regorafenib) that displace the activation segment block RIPK2 autophosphorylation, RIPK2 ubiquitination, and inflammatory NF-κB signaling. Type I (ATP-competitive) inhibition was only poorly effective. A crystal structure of RIPK2 bound to ponatinib was determined, revealing the activation segment conformation and an allosteric site.\",\n      \"method\": \"Crystal structure (first RIPK2 crystal structure), kinase inhibitor profiling, autophosphorylation assay, ubiquitination assay, NF-κB reporter, monocyte cytokine production\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — first crystal structure of RIPK2, type I vs type II inhibitor comparison, ubiquitination and NF-κB mechanistic assays\",\n      \"pmids\": [\"26320862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HIV-1 protease cleaves RIPK2 during infection of T cells. Cleavage was prevented by HIV-1 protease inhibitor but not by inhibitors of RT or integrase. Cleavage of RIPK1 (which was identified at a defined PR cleavage site) disrupted RIPK1/RIPK3 complex formation and NF-κB induction; analogous cleavage of RIPK2 is proposed as a viral immune evasion strategy.\",\n      \"method\": \"HIV-1 infection of T cells, stage-specific inhibitors, co-immunoprecipitation (RIPK1/RIPK3 complex), NF-κB assay, site mutagenesis (RIPK1 cleavage site)\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — RIPK2 cleavage during HIV infection shown with inhibitor controls, but direct mapping of RIPK2 cleavage site and functional consequence for RIPK2 not fully established in the abstract\",\n      \"pmids\": [\"26297639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"WEHI-345, a selective RIPK2 kinase inhibitor, delays but does not abolish RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation, WEHI-345 prevents cytokine production in vitro and in vivo, demonstrating that kinase activity timing is critical for productive immune responses and that RIPK2 kinase activity is required for proper NOD signaling.\",\n      \"method\": \"Selective kinase inhibitor, ubiquitylation kinetics assay, NF-κB activation kinetics, cytokine production assay in vitro/in vivo, EAE model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — selective inhibitor with biochemical mechanistic dissection, in vitro and in vivo validation, independently replicated concept\",\n      \"pmids\": [\"25778803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling. Instead, kinase inhibitors function by antagonizing the XIAP-binding interaction. The XIAP binding site on RIPK2 was mapped to the loop between β2 and β3 of the N-lobe of the kinase domain, in close proximity to the ATP-binding pocket. Inhibitor binding to the ATP pocket sterically blocks the RIPK2-XIAP interaction, preventing XIAP-mediated ubiquitination of RIPK2 and downstream NOD2 signaling.\",\n      \"method\": \"XIAP binding mapping, site-directed mutagenesis, kinase activity assays, co-immunoprecipitation, in vivo NOD2 signaling assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural mapping of XIAP binding site, mutagenesis, multiple inhibitors with orthogonal mechanistic validation\",\n      \"pmids\": [\"30026309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RIPK2 forms detergent-insoluble, higher-order molecular complexes (speck-like structures) in the cytosol upon infection with invasive enteropathogenic bacteria. Complex formation required RIPK2 autophosphorylation at Y474, was influenced by S176 phosphorylation, and depended on the CARD of NOD1 or NOD2. XIAP counteracts RIPK2 complex formation; mutation of XIAP ubiquitylation sites on RIPK2 enhanced complex formation, identifying XIAP-mediated ubiquitination as a brake on RIPK2 aggregation.\",\n      \"method\": \"Detergent fractionation, autophosphorylation site mutagenesis (Y474, S176), XIAP ubiquitylation site mutagenesis, bacterial infection model\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple phosphorylation site mutants, XIAP ubiquitylation site mutants, detergent fractionation, bacterial infection model — all orthogonal\",\n      \"pmids\": [\"31350258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A regulatory region on RIPK2 (distinct from K209) is required for XIAP binding and downstream NOD signaling. Using endogenous FLAG-RIPK2 knock-in mice and site-directed mutagenesis, K48-linked ubiquitination at specific residues was found to control RIPK2 stability, while distinct sites govern XIAP binding and signaling. K209 ubiquitination was not detected during NOD2 signaling at endogenous levels, contrasting with earlier overexpression data.\",\n      \"method\": \"CRISPR/Cas9 FLAG-RIPK2 knock-in mice, site-directed mutagenesis, mass spectrometry-based post-translational modification mapping, NOD2 signaling assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — endogenous-level analysis via CRISPR knock-in, MS-based PTM mapping, mutagenesis; contradicts prior K209 ubiquitination claim under endogenous conditions\",\n      \"pmids\": [\"32954645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ATG16L1 physically binds the RICK/RIPK2 kinase domain and negatively regulates TLR2-mediated NF-κB activation and pro-inflammatory cytokine responses by inhibiting the interaction between TLR2 and RICK/RIPK2. ATG16L1 binding suppresses NF-κB activation by down-regulating RICK polyubiquitination.\",\n      \"method\": \"Co-immunoprecipitation in HEK293 cells and primary human dendritic cells, NF-κB activation assays, cytokine measurement\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP in two cell systems, functional NF-κB assay, single lab\",\n      \"pmids\": [\"32909611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RIPK2 stabilizes c-Myc and promotes prostate cancer metastasis by binding to and activating MKK7, which was identified as a direct c-Myc-S62 kinase. This defines a noncanonical RIPK2/MKK7/c-Myc pathway distinct from the canonical NOD/NF-κB pathway. RIPK2 inhibition inactivated MKK7 and c-Myc-S62 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, multi-level proteomics, RIPK2 knockout, phosphorylation assays (c-Myc S62), kinase inhibitors, in vivo metastasis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifying RIPK2-MKK7 binding, genetic KO, multi-level proteomics, pharmacological inhibition, in vivo validation\",\n      \"pmids\": [\"35115556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NOD2 activation results in increased IRF4 expression, which then binds TRAF6 and RICK. IRF4 binding leads to inhibition of K63-linked polyubiquitination of both TRAF6 and RICK, thereby downregulating NF-κB activation. This defines a negative feedback mechanism where NOD2 activation ultimately suppresses TLR-mediated inflammatory responses.\",\n      \"method\": \"Co-immunoprecipitation (IRF4 binding to TRAF6 and RICK), ubiquitination assays (K63-linkage), in vivo colitis model with MDP/IRF4 treatment\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of IRF4-RICK complex, K63-ubiquitination assays, in vivo validation, single lab\",\n      \"pmids\": [\"24670424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RIP2/RICK/CARDIAK is a direct substrate for pyridinyl imidazole p38 MAPK inhibitors (SB220025, SB203580, PD169316) in vitro, with inhibition at concentrations comparable to p38 inhibition. RIP2 autophosphorylation and its ability to phosphorylate myelin basic protein (Km=2.1 μM) and histone H3 (Km=0.65 μM) were identified as new substrates. A conserved threonine in the RIP2 kinase domain (equivalent to p38) was required for inhibitor sensitivity.\",\n      \"method\": \"In vitro kinase autophosphorylation assay, substrate phosphorylation assay (MBP, histone H3), Km determination, threonine mutant analysis\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted kinase assay with mutagenesis confirming mechanism of inhibitor sensitivity; identified new substrates\",\n      \"pmids\": [\"15724446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CARD6 specifically binds Nod1 (CARD4) and Cardiak (RIPK2) by immunoprecipitation but not other CARD family proteins, and acts as a selective modulator suppressing NF-κB induction by Nod1 or Cardiak. Cardiak and Nod1 had opposing effects on CARD6 phosphorylation and expression. CARD6 did not interfere with CARD-containing adaptor Bcl10 or TNF-α-induced NF-κB nor with caspase-1-dependent IL-1β secretion.\",\n      \"method\": \"Co-immunoprecipitation, NF-κB reporter transfection assay, phosphorylation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and functional reporter assay, specificity confirmed by testing multiple CARD proteins, but single lab, no structural validation\",\n      \"pmids\": [\"12775719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RICK activates NF-κB through its intermediate domain (not kinase activity, as both kinase-active and kinase-inactive forms activated NF-κB) and this NF-κB activation potently blocks HCMV replication in human fibroblasts. A stable IκB inhibitor reversed RICK's anti-HCMV effect. RICK expression synergized with HCMV infection in inducing IFN-β, which was identified as a downstream component of the RICK inhibitory pathway.\",\n      \"method\": \"Kinase-active and kinase-dead RICK overexpression, stable IκB inhibitor, supernatant IFN-β transfer experiments, viral replication assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead vs active domain dissection, stable IκB reversal, IFN-β identification by supernatant transfer; single lab\",\n      \"pmids\": [\"14670961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The CARD of RICK folds as an α-helical Greek key structure with marginal stability (ΔG = 3.0 kcal/mol). Equilibrium folding follows a two-state mechanism, but unfolding and refolding kinetics are complex with at least three non-native conformations and kinetically trapped species, likely involving parallel folding pathways rather than prolyl isomerism.\",\n      \"method\": \"Equilibrium and stopped-flow kinetic folding spectroscopy, chemical denaturation, guanidinium/salt titrations\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous biophysical characterization of CARD folding, but single lab and focuses on folding mechanism rather than signaling function\",\n      \"pmids\": [\"12755636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NOD2 activation by PGN in oligodendrocyte precursor cells (OPCs) leads to RIPK2 recruitment and phosphorylation of RIPK2, followed by phosphorylation of neuronal nitric oxide synthase (nNOS). This increases NOS activity and NO accumulation leading to mitochondrial respiratory enzyme inhibition (complex I and IV), reduced mitochondrial membrane potential, and cytochrome-C release. Intracerebral PGN injection in rats caused CNS demyelination.\",\n      \"method\": \"OPC cultures, NOD2 ligand stimulation, RIPK2 phosphorylation assay, nNOS phosphorylation, NOS activity assay, specific inhibitors (7-NI vs L-canavanine), mitochondrial function assays, in vivo rat injection\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation cascade demonstrated with selective inhibitors, in vitro and in vivo, but single lab\",\n      \"pmids\": [\"24169446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MYSM1 deubiquitinates RIPK2 and dephosphorylates RIPK2 at S176 by recruiting protein phosphatase 2A (PP2A) to RIPK2. This attenuates NF-κB and MAPK signaling. The Ripk2S176D (phosphomimetic) mutation accelerated OA pathogenesis, while Ripk2 silencing or Ripk2S176A mutation deactivated NF-κB and MAPK pathways and counteracted the role of MYSM1.\",\n      \"method\": \"Co-immunoprecipitation (MYSM1-PP2A-RIPK2 complex), S176 phosphomimetic and phospho-dead mutagenesis in mice, deubiquitination assays, NF-κB/MAPK signaling assays, in vivo OA mouse model\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical deubiquitination and dephosphorylation assays, phospho-site mutagenesis in vivo, multiple orthogonal methods identifying MYSM1-PP2A as writer/eraser of RIPK2 PTMs\",\n      \"pmids\": [\"39746943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"YOD1, a deubiquitinating enzyme, inhibits K48-linked polyubiquitination of RIPK2, preventing its proteasomal degradation and thereby increasing RIPK2 abundance to enhance NOD2 signaling. YOD1-deficient mice show increased susceptibility to DSS-induced colitis, and the protective function of the NOD2 ligand MDP in experimental colitis was abolished in YOD1-deficient mice.\",\n      \"method\": \"YOD1-deficient mice, bone marrow transplantation, K48-ubiquitination assays, NOD2 signaling assays in macrophages, DSS colitis model\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with K48-ubiquitination linkage assay, bone marrow transplant epistasis, in vivo colitis model, multiple orthogonal validations\",\n      \"pmids\": [\"39333628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"N4BP3 interacts with RIPK2 (demonstrated by co-immunoprecipitation) and promotes K63-linked ubiquitination of RIPK2, further promoting the NOD2-MAPK/NF-κB pathway and increasing pro-inflammatory cytokine release. N4BP3 knockdown reduced MDP-induced inflammatory cytokines and NOD2-pathway phosphoproteins (ERK1/2, JNK, P38, NF-κB p65).\",\n      \"method\": \"Co-immunoprecipitation, K63-ubiquitination assay, siRNA knockdown, MDP stimulation, phosphoprotein immunoblotting, in vivo DSS colitis\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrated N4BP3-RIPK2 interaction, K63-ubiquitination assay, functional signaling readouts; single lab\",\n      \"pmids\": [\"39420190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RIPK2 promotes colorectal cancer metastasis through a mechanism involving K63-linked ubiquitination of RIPK2 (triggered by MDP/NOD2 activation), and RIPK2 interaction with the E3 ubiquitin ligase ITCH which balances K63-ubiquitination of RIPK2 with K48-ubiquitination of YAP (leading to YAP degradation). RIPK2 knockdown increased ITCH-mediated K48-ubiquitination and degradation of YAP. GSK583 (RIPK2 inhibitor) disrupted YAP stability.\",\n      \"method\": \"Co-immunoprecipitation (RIPK2-ITCH interaction), ubiquitination linkage assays (K63/K48), RIPK2 knockdown, pharmacological inhibition, in vivo xenograft and metastasis models, proteomic analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, linkage-specific ubiquitination assays, pharmacological inhibitor, in vivo model; single lab, relatively recent study\",\n      \"pmids\": [\"40185717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RIPK2 interacts with PRKCI (as shown by co-immunoprecipitation and immunofluorescence) to enhance phosphorylation of NF-κB, JNK, and ERK downstream. RIPK2 knockout suppressed subcutaneous tumor growth, liver metastasis, inhibited autophagosome formation, and increased ROS production and apoptosis in pancreatic cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, RIPK2 knockout, phosphorylation immunoblotting, in vivo xenograft and metastasis models\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of RIPK2-PRKCI, phosphorylation assays, genetic KO with in vivo validation; single lab\",\n      \"pmids\": [\"37016317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Card9 inhibits NLRP3 inflammasome activation in macrophages by recruiting Ripk2. Ripk2 competitively binds Caspase-1, preventing the normal ASC-Caspase-1 interaction required for NLRP3 inflammasome assembly. Overexpression of Ripk2 alleviated septic intestinal injury caused by Card9 deficiency.\",\n      \"method\": \"Co-immunoprecipitation (Card9-Ripk2; Ripk2-Caspase-1 vs ASC-Caspase-1 competition), Card9-knockout mice, NLRP3 inflammasome activation assay, Ripk2 overexpression rescue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competitive Co-IP dissecting caspase-1 binding partners, genetic KO and rescue with overexpression; single lab, novel mechanism\",\n      \"pmids\": [\"35618701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A co-crystal structure of RIPK2 bound to the activation loop targeting inhibitor CSR35 revealed a resolved activation loop with an ionic interaction between the inhibitor carboxylic acid and the side-chain of Lys169 in the activation loop, providing structural basis for activation-loop-targeting type II inhibitor strategy and >10-fold selectivity over VEGFR2.\",\n      \"method\": \"Co-crystal structure of RIPK2-CSR35 complex, biochemical kinase inhibition assay\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with explicit activation loop resolution and selectivity-determining ionic contact identified; single lab\",\n      \"pmids\": [\"29409752\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RIPK2 (RICK/CARDIAK/CARD3) is a dual-specificity serine/threonine/tyrosine kinase with an N-terminal kinase domain and C-terminal CARD that acts as the obligate adaptor kinase downstream of NOD1 and NOD2 pattern-recognition receptors: upon bacterial peptidoglycan sensing, RICK is recruited via homotypic CARD-CARD interactions (requiring acidic NOD1 and basic RICK CARD residues) to the plasma membrane where its activity is optimal; it undergoes autophosphorylation (including at Y474 and S176) and K63-linked polyubiquitination (facilitated by XIAP as the primary E3 ligase, and regulated by N4BP3 and other ligases, with K48-linked ubiquitination by opposing enzymes controlling its stability); the scaffolding function—specifically the RIPK2-XIAP protein-protein interaction mediated by the β2-β3 loop of the kinase N-lobe—is mechanistically more critical than catalytic activity for recruiting TAK1 and activating the IKK complex to drive NF-κB and MAPK-dependent pro-inflammatory cytokine production; XIAP-mediated ubiquitination also prevents formation of higher-order RIPK2 speck-like complexes; in addition to the canonical NOD pathway, RIPK2 signals downstream of T-cell receptors, IL-1/IL-18 receptors, and certain TLRs, mediates a noncanonical MKK7/c-Myc pathway relevant to cancer metastasis, and can be inactivated by pathogen-derived proteases (P. gingivalis Kgp gingipain, HIV-1 protease) and bacterial effectors (Yersinia YopJ acetylation) as immune evasion mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RIPK2 (RICK/CARDIAK/CARD3) is a dual-domain serine/threonine kinase with an N-terminal kinase domain and a C-terminal CARD that functions as the obligate adaptor kinase coupling the cytosolic pattern-recognition receptors NOD1 and NOD2 to NF-\\u03baB and MAPK-driven pro-inflammatory cytokine production [#5, #2]. Recruitment occurs through homotypic CARD-CARD engagement that is critically dependent on a set of acidic residues on the NOD1 CARD pairing with basic residues on the RIPK2 CARD [#4], and NOD2 directs RIPK2 to the plasma membrane where signaling is optimal\\u2014a step disrupted by the Crohn's disease-associated NOD2 1007FS mutant [#7]. Once recruited, RIPK2 propagates signaling primarily as a scaffold rather than a catalyst: K63-linked polyubiquitination recruits TAK1 to activate the IKK complex [#6], and the interaction between RIPK2 and the E3 ligase XIAP\\u2014mediated by the \\u03b22-\\u03b23 loop of the kinase N-lobe adjacent to the ATP pocket\\u2014is mechanistically more important than catalytic activity for productive NOD signaling, explaining why ATP-competitive and type II kinase inhibitors act largely by sterically blocking the RIPK2-XIAP interface [#13, #10]. RIPK2 also undergoes autophosphorylation at Y474 and S176 that governs assembly of higher-order detergent-insoluble speck-like complexes, a process restrained by XIAP-mediated ubiquitination [#14]. The pathway connects upstream to oligomerization-induced NF-\\u03baB activation via the intermediate region and IKK\\u03b3/NEMO [#2], and RIPK2 additionally operates downstream of TLR2/3/4 and IL-1/IL-18 receptors and in T-cell receptor signaling required for IL-2 production and TH1 differentiation [#3]. RIPK2 abundance and activity are tuned by an opposing set of writers and erasers acting on its ubiquitination and phosphorylation\\u2014including K48-ubiquitin control of stability, the deubiquitinases YOD1 and MYSM1, and the K63-promoting ligase-associated factor N4BP3 [#15, #25, #24, #26]\\u2014and the kinase is targeted for inactivation by pathogen-derived enzymes including Yersinia YopJ acetylation of its activation loop and gingipain (Kgp) proteolysis [#8, #9]. Beyond canonical innate immunity, RIPK2 drives cancer metastasis through a noncanonical pathway in which it binds and activates MKK7 to stabilize c-Myc [#17].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established RIPK2's basic architecture and first signaling outputs, framing it as a CARD-containing kinase linking death/inflammatory adaptors to NF-\\u03baB, JNK, and caspase activation.\",\n      \"evidence\": \"Co-IP, overexpression, dominant-negative K38M mutagenesis, and NF-\\u03baB/JNK reporter and apoptosis assays identifying interactions with CLARP/caspase-8, caspase-1, and TRAFs\",\n      \"pmids\": [\"9575181\", \"9705938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Overexpression-based; physiological receptor context not yet defined\", \"Whether kinase activity or scaffolding drives each output unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined an induced-proximity model whereby RIPK2 oligomerization engages IKK\\u03b3/NEMO through its intermediate region, not its kinase domain, to activate NF-\\u03baB downstream of NOD1.\",\n      \"evidence\": \"Co-IP, enforced oligomerization, dominant-negative IKK\\u03b3, and NF-\\u03baB reporter assays\",\n      \"pmids\": [\"10880512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How endogenous receptor engagement triggers oligomerization not shown\", \"Role of ubiquitination in IKK recruitment not yet addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetically placed RIPK2 downstream of multiple immune receptors, showing it is required for innate responses (TLR2/3/4, NOD, IL-1/IL-18) and adaptive T-cell function.\",\n      \"evidence\": \"Rip2-deficient mouse cells with recruitment Co-IP, cytokine, NF-\\u03baB, T-cell proliferation and TH1 differentiation readouts\",\n      \"pmids\": [\"11894098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Breadth of TLR involvement later narrowed by cleaner agonist studies\", \"Direct versus indirect roles in adaptive immunity not fully separated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided in vitro enzymatic characterization, identifying substrates and the residue conferring pyridinyl imidazole inhibitor sensitivity.\",\n      \"evidence\": \"In vitro autophosphorylation and substrate (MBP, histone H3) kinase assays with Km determination and conserved threonine mutant analysis\",\n      \"pmids\": [\"15724446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of MBP/H3 as substrates unestablished\", \"In vitro substrates may not reflect in-cell targets\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the structural basis of NOD1-RIPK2 CARD-CARD recognition, identifying the electrostatic interface essential for downstream signaling.\",\n      \"evidence\": \"NMR structure of NOD1 CARD with mutagenesis of acidic/basic residue pairs, Co-IP, and NF-\\u03baB reporter validation\",\n      \"pmids\": [\"17054981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NOD2 CARD interface not structurally resolved here\", \"Affinity and stoichiometry of the assembled complex not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the central signaling steps: clean genetic placement downstream of NOD1/NOD2, K63-ubiquitination at K209 recruiting TAK1, and NOD2-driven membrane recruitment as the site of optimal signaling.\",\n      \"evidence\": \"RICK-null macrophages, K209 mutagenesis and ubiquitination assays with TAK1-deficient cells, and membrane-targeting/fractionation constructs including the NOD2 1007FS mutant\",\n      \"pmids\": [\"17277144\", \"18079694\", \"17355968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"K209 ubiquitination later not detected at endogenous levels\", \"E3 ligase responsible for K63 chains not identified at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed RIPK2 as a target of bacterial immune-evasion enzymes that inactivate it by distinct mechanisms.\",\n      \"evidence\": \"In-cell acetylation assay with catalytically dead YopJ control, and cell-free proteolysis with Kgp-specific inhibitor and isogenic Kgp-deficient P. gingivalis\",\n      \"pmids\": [\"22520462\", \"22685397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RIPK2 acetylation and cleavage sites not fully mapped\", \"Consequences for higher-order complex assembly not examined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Dissected the kinase-activity-versus-scaffold question with structures and selective inhibitors, showing type II inhibitors block autophosphorylation, ubiquitination, and NF-\\u03baB signaling while kinase activity timing tunes productive responses.\",\n      \"evidence\": \"First RIPK2 crystal structure with ponatinib, type I vs type II inhibitor profiling, and the selective inhibitor WEHI-345 with ubiquitylation kinetics and in vivo/EAE readouts\",\n      \"pmids\": [\"26320862\", \"25778803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular reason inhibitors block ubiquitination not yet defined (resolved later)\", \"Distinction between catalytic and non-catalytic inhibitor effects unresolved here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended the proteolytic-inactivation theme to viral infection, implicating HIV-1 protease cleavage of RIPK2 as a candidate immune-evasion strategy.\",\n      \"evidence\": \"HIV-1 infection of T cells with stage-specific protease/RT/integrase inhibitors and Co-IP of the related RIPK1/RIPK3 complex\",\n      \"pmids\": [\"26297639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RIPK2 cleavage site not mapped\", \"Functional consequence for RIPK2 signaling not directly demonstrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the inhibitor mechanism by mapping the XIAP-binding site to the \\u03b22-\\u03b23 loop near the ATP pocket, establishing that inhibitors act by blocking the RIPK2-XIAP interaction rather than catalysis.\",\n      \"evidence\": \"XIAP binding mapping, site-directed mutagenesis, kinase assays, Co-IP, and in vivo NOD2 signaling, plus a co-crystal structure of RIPK2 with the activation-loop inhibitor CSR35 defining a Lys169 ionic contact\",\n      \"pmids\": [\"30026309\", \"29409752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the RIPK2-XIAP complex not fully defined\", \"How XIAP ubiquitination is coupled to TAK1/IKK recruitment not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected RIPK2 autophosphorylation to higher-order assembly, showing Y474/S176 phosphorylation drives speck-like complex formation that XIAP-mediated ubiquitination restrains.\",\n      \"evidence\": \"Detergent fractionation with Y474/S176 and XIAP-ubiquitylation-site mutagenesis in bacterial infection models\",\n      \"pmids\": [\"31350258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional output of speck assembly versus signaling not fully separated\", \"Structure of the higher-order complex unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Refined the ubiquitin code at endogenous levels, distinguishing K48 control of stability from a separate XIAP-binding regulatory region, and identifying the MYSM1-PP2A axis as an eraser of RIPK2 ubiquitination and S176 phosphorylation.\",\n      \"evidence\": \"CRISPR FLAG-RIPK2 knock-in mice with MS-based PTM mapping and mutagenesis; MYSM1-PP2A-RIPK2 Co-IP with S176 phosphomimetic/phospho-dead mutants in an OA model\",\n      \"pmids\": [\"32954645\", \"39746943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the K48 ligase(s) controlling stability not pinned down\", \"Reconciliation with prior K209 ubiquitination model only partially addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a noncanonical, oncogenic RIPK2 pathway in which it binds and activates MKK7 to phosphorylate and stabilize c-Myc, driving metastasis independent of NOD/NF-\\u03baB.\",\n      \"evidence\": \"Co-IP, multi-level proteomics, RIPK2 knockout, c-Myc-S62 phosphorylation assays, inhibitors, and in vivo metastasis models\",\n      \"pmids\": [\"35115556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RIPK2 selects MKK7 over canonical effectors not defined\", \"Relationship between scaffolding and catalytic requirements in this pathway unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the network of opposing ubiquitin enzymes tuning RIPK2 abundance and activity, with YOD1 protecting RIPK2 from K48-degradation and N4BP3 promoting activating K63 chains.\",\n      \"evidence\": \"YOD1-deficient mice with K48-linkage assays and DSS colitis; N4BP3 Co-IP, K63-ubiquitination assays, siRNA knockdown, and phosphoprotein readouts\",\n      \"pmids\": [\"39333628\", \"39420190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzyme-substrate kinetics not established for N4BP3\", \"Whether YOD1 and XIAP act on overlapping sites unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RIPK2's canonical scaffolding/ubiquitination machinery is repurposed in its noncanonical oncogenic and inflammasome-modulating roles, and how the full set of writer/eraser enzymes is coordinated in vivo, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM state to choice between NOD/NF-\\u03baB, MKK7/c-Myc, and caspase-1 modulation\", \"Structure of the assembled NOD-RIPK2-XIAP-TAK1 signaling node not determined\", \"Relative in vivo contribution of catalytic versus scaffold functions across tissues unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [19, 17, 23]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [19, 0, 6]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 6, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 3, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 17, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NOD1\", \"NOD2\", \"XIAP\", \"TAK1\", \"IKBKG\", \"TRAF6\", \"MAP2K7\", \"PRKCI\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}